Orbimed Advisors Llc - Jan 20, 2022 Form 4/A - Amendment Insider Report for Passage BIO, Inc. (PASG)

Role
10%+ Owner
Signature
/s/ Carl Gordon Member of OrbiMed Advisors LLC
Stock symbol
PASG
Transactions as of
Jan 20, 2022
Transactions value $
$254,000
Form type
4/A - Amendment
Date filed
5/5/2022, 05:11 PM
Date Of Original Report
Jan 24, 2022
Previous filing
Jan 21, 2022
Next filing
Jan 27, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PASG Common Stock Purchase $254K +50.8K +0.81% $5.00* 6.32M Jan 20, 2022 See Footnotes F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On January 24, 2022, the Reporting Person filed a Form 4 which inadvertently reported the incorrect number and purchase price of shares of the Issuer's common stock ("Shares") purchased by the reporting person on January 20, 2022. This amendment provides the correct number and purchase price of the Shares purchased and correctly reflects the number of Shares owned by the Reporting Person following such purchase.
F2 These Shares were purchased in a block order at a price of $5.00.
F3 The Shares are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationship, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII.
F4 Each of GP VII and OrbiMed Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.